Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Portrait de John D. Mendlein
Leeftijd : 60
Vermogen : 11 680 079 USD
Belangrijkste bedrijven : Fate Therapeutics, Inc. - Omega Therapeutics, Inc.
Overzicht 
Founder of Fate Therapeutics, Inc. and Homes for Sudan, John D. Mendlein is a businessperson who has been at the helm of 6 different companies and occupies the position of Chairman at Chimeros Therapeutics, Chairman of Kintai Therapeutics, Inc., Chairman at Senda Biosciences, Inc., Executive Partner at Flagship Pioneering and President-Corporate & Product Strategy at ModernaTX, Inc. Dr. Mendlein is also on the board of 7 other companies.

In his past career Dr. Mendlein was Independent Director at aTyr Pharma, Inc., Attorney at Cooley LLP, President-Corporate & Product Strategy at Moderna, Inc., Chairman & Chief Executive Officer for Adnexus, Chairman & Chief Executive Officer of Affinium Pharmaceuticals Ltd., Scientist at GlaxoSmithKline Pharmaceuticals SA (Belgium) and Director & Chief Knowledge Officer at Aurora Biosciences Corp.

John D. Mendlein received a doctorate from the University of California, Los Angeles, an undergraduate degree from the University of Miami and a graduate degree from the University of California, Hastings.


Posities en verantwoordelijkheden van John D. Mendlein 
NaamTitel Van
Fate Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Vice Chairman 2011
Omega Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Director 2020
Chimeros Therapeutics Chairman -
Kintai Therapeutics, Inc. Chairman 2020
Senda Biosciences, Inc. Chairman -
Biotechnology Innovation Organization Director -
ModernaTX, Inc. President-Corporate & Product Strategy 2018
Homes for Sudan Director -
Ohana Biosciences, Inc. Director -
Repertoire Immune Medicines, Inc. Director -
Tessera Therapeutics, Inc. Director -
Flagship Pioneering Executive Partner 2019


Belangnemingen van John D. Mendlein 
NaamAandelen%Totale waarde
Fate Therapeutics, Inc. (FATE)
(Biotechnologie & Medisch Onderzoek)
159 4550,17%11 680 079 USD
Omega Therapeutics, Inc. (OMGA)
(Biotechnologie & Medisch Onderzoek)
00,0000%0 USD


John D. MendleinPersoonlijk netwerk 
Meest gelezen nieuws 
22/09WILLIAM ACKMAN : Ackman's Pershing Square fonds stijgt bij beursdebuut Universal
MR
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
24/09CATHIE WOOD : Chinese maatregelen tegen bitcoin opnieuw een klap voor Cathie Woods ARK ETF
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
John D. Mendlein Verbindingen